| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | IDRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $242.24M | Series B | 8/7/2024 | $120.24M | $414.65M | $6.44 | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | ||||
 | Immune-Onc Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $143.15M | Series B3 | 1/6/2023 | $30M | $262.2M | $2.11 | Triwise Capital, Proxima Ventures | ||||
 | InflammX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Intact Vascular | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | ||||
 | LocanaBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $318M | Series B | 12/14/2020 | $100M | $317.84M | $4.42 | Vida Ventures, RA Capital Management, Invus, Acuta Capital Partners, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures, GV | ||||
 | Lyell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.04B | Series C | 3/5/2020 | $493M | $2.5B | $11.49 | ARCH Venture Partners, Foresite Capital, Milky Way Investments | ||||
 | Metabiota | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $84.22M | Series B | 3/7/2017 | $8.02M | $156.11M | $1.84 | WP Global Partners, In-Q-Tel, SharesPost | ||||
 | Metacrine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Nautilus Biotechnology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Neogene Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125M | Series A | 9/14/2020 | $110M | $241.63M | $12.47 | EcoR1 Capital, Jeito Capital, Syncona, Polaris Partners, Pontifax, Vida Ventures, TPG, Two River | ||||
 | Neumora | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $612.4M | Series B | 10/11/2022 | $112.4M | $1.33B | $1.50 | Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners | ||||
 | Noctrix Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.87M | Series C-1 | 8/11/2020 | $13.31M | $317.71M | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | ||||
 | Omega Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Omniox | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | One Medical Group | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $437.68M | Series I | 8/22/2018 | $250M | $1.5B | $12.43 | The Carlyle Group | ||||
 | Orbital Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $373M | Series A | 4/26/2023 | $270M | $705.88M | $1.50 | ARCH Venture Partners, Andreessen Horowitz, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems | ||||
 | PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.82M | Series C | 8/25/2020 | $42.65M | $425.93M | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | ||||
 | Pharmazz | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.22M | Series A | 6/11/2025 | $25M | $216.61M | $5.89 | Sun Pharma | ||||
 | Promedior | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Pyxis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.5M | Series B | 3/30/2021 | $172.5M | $273.43M | $10.47 | Arix Bioscience, RTW Investments, Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital, LifeSci Venture Partners, Leaps by Bayer, Agent Capital, Ipsen Ventures, Longwood Fund, 3E Bioventures | ||||
 | Rapport Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.18M | Series B | 8/7/2023 | $150M | $409.19M | $1.68 | Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation | ||||
 | Scipher Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.76M | Series D | 2/24/2022 | $120.72M | $498.65M | $38.12 | Cowen Healthcare Investments, Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Northpond Ventures, aMoon, Khosla Ventures, Optum Ventures, Echo Health Ventures, Alumni Ventures | ||||